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Abstract 
Background: Anti‑T2 biological therapies have proven to effectively reduce acute exacerbations and daily doses of 
oral steroids in severe eosinophilic asthma. Despite the remarkable clinical efficacy, there are usually only moderate 
improvements in airflow limitation, suggesting that other measures of lung function like small airway dysfunction 
(SAD) might better reflect the clinical response. We aimed to investigate if measures of small airway function would 
predict and correlate with the clinical response to anti‑T2 therapy.
Methods: We studied data of patients who were previously included in the German prospective longitudinal All Age 
Asthma Cohort (ALLIANCE) that recruits asthma patients of all severity grades and inflammatory phenotypes. The 
selection criteria for this analysis were adult patients with severe eosinophilic asthma under treatment with anti‑T2 
biological agents. Asthma control was assessed by asthma control test (ACT) and number of severe exacerbations. 
Small airway function was assessed by the frequency dependence of resistance (FDR, R5‑20)) derived from impulse 
oscillometry (IOS) and the mean forced expiratory flow between 25 and 75% of the forced vital capacity  (FEF25‑75). We 
also studied air trapping (RV and RV/TLC), blood eosinophils and FeNO. Patients were classified into responders and 
partial or non‑responders. Clinical response was defined as at least 50% reduction in annualized severe exacerbations 
and daily oral steroid doses accompanied with a minimum increase of 3 points in the ACT score. We used a Receiver 
Operator Characteristic (ROC) to study the capacity of FDR in predicting clinical response compared to other clinical 
variable like blood eosinophils. We studied the correlation between FDR measures and clinical response, represented 
by the ACT score and number of exacerbations, using linear regressions.
Results: 20 patients were included (mean age, 59 ± 9 years; 60% female; mean body mass index (BMI), 27.6 ± 5.4 kg/
m2; mean absolute blood eosinophils, 570 ± 389/µl; mean number of severe exacerbations 12 months prior to 
initiating the biological therapy, 5.0 ± 3; mean predicted FEV1, 76 ± 21%; mean predicted FDR, 224 ± 140%; mean 
daily prednisolone dose, 6.4 ± 4.9 mg; mean ACT score, 15 ± 5). Responders had significantly higher baseline FDR 
compared to partial or non‑responders but similar FEV1,  FEF25–75, RV and RV/TLC. ROC analysis showed that the 
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To the Editor,
Anti-T2 biological therapy is recommended as an add-
on treatment for severe eosinophilic asthma [1]. Several 
randomized clinical trials have demonstrated the efficacy 
of anti-T2 therapy in reducing acute exacerbations and 
daily doses of oral steroids, while also indicating some 
improvements in forced expiratory volume in 1 s (FEV1) 
[2–4]. The improvements in FEV1 do not seem to corre-
spond properly with the marked clinical response to bio-
logical therapy, suggesting that measures of large airway 
obstruction like the FEV1 might be a poor tool and that 
measures of other lung function abnormalities like small 
airway dysfunction (SAD) might better reflect the clini-
cal response. Indeed, SAD is a hallmark of asthma that 
is associated with disease severity and poor symptom 
control [5]. Moreover, SAD is associated with frequent 
exacerbations [6, 7] and has a negative impact on daily 
physical activity [8]. We aimed to investigate if meas-
ures of SAD in patients with severe eosinophilic asthma 
might better correlate or even be helpful in predicting 
clinical response to biological therapy, thereby potentially 
describing a distinct phenotype within this severe asthma 
population.
In this study, we analyzed data of patients who were 
previously recruited in the prospective longitudinal All 
Age Asthma Cohort (ALLIANCE), a national cohort of 
pediatric and adult patients with asthma in Germany, ini-
tiated by the German Centre for Lung Research (DZL). 
The study was approved by the local ethics committee 
at the medical school Luebeck (Az.21–215) and is reg-
istered at clinicaltrials.gov (adult arm: NCT02419274) 
[9]. Since 2014, the adult arm of the ALLIANCE cohort 
recruits patients with mild to severe asthma and healthy 
controls. Patients had to be in specialist care for more 
than three months, and criteria of “difficult to control” 
asthma were addressed according to current guide-
lines [10]. Study visits take place in 12 months intervals. 
Patients had to have stable disease without acute exacer-
bations or respiratory tract infections within four weeks 
prior to study visits.
The selection criteria for this study were adult patients 
with severe eosinophilic asthma in whom a treatment 
with anti-T2 biological agent has been initiated while 
already being recruited into the observational ALLI-
ANCE study and in whom at least one complete fol-
low-up visit was available. Indication, prescription and 
administration of the biological therapy were not part 
of the study but rather were done by their respiratory 
physicians.
On each study visit, we assessed asthma control by 
asthma control test (ACT) as well as number of severe 
exacerbations 12 months prior to the study visit, defined 
as a burst of systemic corticosteroids for ≥ 3  days [10]. 
We performed a spirometry, body plethysmography 
and impulse oscillometry (Masterscreen Body and 
IOS, Vyaire Medical, Germany) according to guidelines 
[11–13]. IOS is a feasible diagnostic tool that measures 
increased resistance in peripheral airways at tidal breath-
ing, even in subjects with normal spirometry [14]. We 
studied the small airway function using both spirom-
etry measures  (FEF25–75) and IOS measures (frequency 
dependence of resistance, FDR (R5Hz-R20Hz, kPa/l/s)). 
Percent predicted FDR values (FDR %pred.) were calcu-
lated according to recently provided prediction equations 
by the German KORA cohort [15]. We also included 
measures of air trapping like the residual volume (RV) 
and RV to total lung capacity ratio (RV/TLC) as indirect 
markers for SAD. We studied peripheral blood eosino-
phils and fractional exhaled nitric oxide (FeNo) as sur-
rogates for eosinophilic airway inflammation [16, 17]. 
Based on their clinical response, patients were classified 
into responders and partial-/non-responders: Respond-
ers (n = 13) had at least a 50% reduction of severe exac-
erbations averaged over the last 12  months or ≥ 50% 
reduction in oral steroid doses [2, 18] and additionally, an 
increase in the ACT score by at least 3 points as this is 
the minimal clinically important difference (MCID) [19]. 
Partial-/Non-responders had less than 50% reduction 
in both severe exacerbations and in oral steroid doses 
and the ACT increase was beneath the MCID, or they 
even experienced worsening of symptoms (i.e. increase 
combination of FDR and blood eosinophils had the best predictive capacity of the clinical response among all tested 
clinical markers (FeNO, FEV1, FDR, blood eosinophils) with an AUC of 85% [67–100%], (CI = 0.95, p = 0.01). Linear 
regressions indicated better associations between improvements in FDR and ACT score  (R2 = 0.42, p = 0.001) than 
with FEV1 and ACT score  (R2 = 0.25, p = 0.013). Likewise, we observed better associations between improvements in 
FDR and reduction of exacerbations  (R2 = 0.41, p = 0.001) than with FEV1  (R2 = 0.20, p = 0.025).
Conclusion: Our data suggest that severe SAD may represent a distinct phenotype of eosinophilic asthma that sub‑
stantially improves under anti‑T2 biological therapy. Measures of small airway function might be useful in selecting 
appropriate patients qualifying for anti‑T2 biological therapy in addition to blood eosinophil count.
Keywords: Anti‑T2 biologics, Asthma control, Small airways dysfunction, FEV1
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in severe exacerbations and a decrease in the ACT score) 
upon tapering systemic steroids. We evaluated the capac-
ity of baseline FDR in predicting clinical treatment 
response by creating a Receiver Operator Characteristic 
(ROC). To evaluate FDR measures as potential markers 
for clinical response, we carried out comparative linear 
regressions between the change in FDR and other lung 
function measures with the change in severe exacerba-
tions and in the ACT score.
Twenty patients with severe eosinophilic asthma under 
a treatment with anti-T2 agents (mepolizumab, n = 18; 
benralizumab, n = 1; dupilumab, n = 1) were included, 
(mean age, 59 ± 9  years; 60% female; mean body mass 
index (BMI), 27.6 ± 5.4  kg/m2). All patients were on 
inhaled corticosteroids (ICS; mean inhaled fluticasone 
Table 1 Clinical characteristics of Responders and Partial-/Non-Responders at baseline and under treatment with Anti-T2 
biological therapy
Values at baseline and under treatment, as well as means of differences (+ or -) are presented as means ± standard deviations
Absolute blood eosinophils (cells/µl), FEV1: forced expiratory volume in the 1 s (l), FEF25-75: forced expiratory flow between 25 and 75% of the forced vital capacity, RV: 
residual volume, TLC: total lung capacity, FDR (%): frequency dependence resistance (R5-20 kPa/l/s) and predicted values, FeNO: fractional exhaled nitric oxide (ppb), 
ACT: asthma control test score, number of exacerbations in the last 12 months, OCS: oral corticosteroid (mg)
P values according to an appropriate test (t. test or Wilcoxon test). P-values in the last column represent test of baseline data vs. data under anti-T2 biological 
treatment within each of the two groups (responders vs. partial/non-responders). At baseline, clinical variables were also tested between groups and did not show 
any significant differences, except for FDR%pred (p = 0.038)
Variable Baseline Under treatment Mean of difference Percentage 
change (%)
P- Value
Responders (n = 13)
Age (years) 59.4 ± 9.8
Sex (f/m) (9/4)
BMI (kg/m2) 26.4 ± 6.1
Blood eosinophil count (/μL) 620.8 ± 378.8 97.7 ± 160.7 − 523.1 − 84  < 0.01
FEV1(l) 2.1 ± 0.88 2.6 ± 1.1 + 0.520 + 24  < 0.01
FEV% 75.8 ± 21.7% 96.2 ± 18.1% + 20.4% + 26  < 0.01
FEF25–75 (l/s) 1.03 ± 0.77 1.64 ± 1.06 + 0.61 + 59  < 0.01
RV% 153 ± 21% 121 ± 20% − 32% − 21 0.02
RV/TLC 48 ± 9% 38 ± 9% − 10% − 21 0.02
FDR (KPa/l/s) 0.26 ± 0.20 0.12 ± 0.16 − 0.13 − 50  < 0.01
FDR%pred 270% ± 151 168% ± 85 − 103% − 37 0.02
FeNo(ppb) 56.1 ± 26.4 40.8 ± 27.5 − 15.31 − 27  < 0.01
ACT score 14.2 ± 5.3 19.8 ± 4.7 + 5.5 + 39  < 0.01
Number of exacerbations 5.5 ± 3.1 1.1 ± 1.2 − 4.4 − 80  < 0.01
OSC dose (mg) 5.9 ± 5 0.4 ± 0.9 − 5.5 − 93  < 0.01
Partial-/non-responders (n = 7)
Age (years) 60.86 ± 8.30
Sex (f/m) (3/4)
BMI (kg/m2) 29.86 ± 3.0
Blood eosinophil count (/μL) 474.3 ± 420.1 200.0 ± 355.9 − 274.2 − 58  > 0.05
FEV1 (l) 2.0 ± 0.58 1.7 ± 0.41 − 0.343 − 17  > 0.05
FEV% 77.6 ± 22.7% 67.1 ± 20.5% − 10.4% − 13  > 0.05
FEF25–75 (l/s) 1.13 ± 0.72 0.81 ± 0.45 − 0.32 − 28  > 0.05
RV% 140 ± 29% 150 ± 29% + 10% + 7  > 0.05
RV/TLC 45 ± 8% 50 ± 3% + 5% + 11  > 0.05
FDR (KPa/l/s) 0.13 ± 0.11 0.23 ± 0.17 + 0.10 + 76  > 0.05
FDR%pred 146% ± 76% 209% ± 151% + 63% + 43  > 0.05
FeNo (ppb) 41.4 ± 43.7 57.9 ± 38.7 + 16.4 + 39  > 0.05
ACT score 17.9 ± 4.9 17.3 ± 3.6 − 0.571 − 3  > 0.05
Number of exacerbations 4.1 ± 2.9 3.0 ± 2.0 − 1.14 − 27  > 0.05
OSC dose (mg) 7.2 ± 5.1 4.7 ± 3.7 − 2.6 36  > 0.05
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equivalent 818 ± 403  µg) and long-acting β2 adrenocep-
tor agonists (LABA). 55% were treated with long-acting 
muscarinic receptor antagonists (LAMAs) and 80% 
were on maintenance oral corticosteroids (OCS, mean 
daily prednisolone dose 6.4 ± 4.9  mg) prior to starting 
with biological therapies. Mean predicted  FEV1 at base-
line was 76 ± 21%, mean  FEF25-75 1.1 ± 0.73 (l/s), mean 
predicted RV 148 ± 25%, mean RV/TLC 47 ± 8%, mean 
FDR 0.21 ± 0.18 kPa/L/s, mean FDR%pred. 224% ± 140%, 
mean absolute blood eosinophils 570 ± 389/µl, mean 
FeNO 60 ± 33  ppb. Mean ACT score was 15.5 ± 5.4 
points and patients experienced 5 ± 3 severe exacerba-
tions 12 months prior to initiating the biological therapy. 
Between responders and partial-/non-responder, there 
were no significant differences in the baseline values of 
all clinical variables except for FDR%pred, which was 
significantly higher in responders (Table  1). Area under 
the curve (AUC) for FDR%pred. was better than for 
FeNO, blood eosinophils, and FEV1 (Table  2). At a cut 
off of 191% for FDR%, we observed a sensitivity of 75%, 
specificity of 71% and AUC of 79% [59–99%] (CI: 0.95, 
p = 0.035). The best AUC was achieved by combining 
FDR%pred. with blood eosinophils count. At cut off val-
ues for FDR of 216%pred, and blood eosinophils of 365/
μL, the ROC curve showed a sensitivity of 75%, specificity 
Table 2 Area under the curve (AUC) of clinical predictors
Areas under the curves from (Fig. 1) used to compare the accuracy of each 
tested marker. P-Values and confidence intervals to define significant test 
(p > 0.05)
Clinical marker AUC P-value 95% Confidence Interval
Lower limit Upper limit
FDR% 0.79 0.03 0.59 0.99
FeNO 0.76 0.06 0.49 1.00
Blood eosinophils 0.64 0.31 0.36 0.93
FEV1% 0.44 0.67 0.14 0.74
FeNO and blood eosino‑
phils
0.72 0.10 0.46 0.99
FEV1 and blood eosino‑
phils
0.66 0.23 0.39 0.94
FDR and blood eosinophils 0.85 0.01 0.67 1.00
Fig. 1 Receiver Operator Characteristic (ROC) curve: x axis (1‑specifecity), y‑axis sensitivity, each curve represents the predictability of each clinical 
marker (in different colors). AUC values and p‑values for the separate variables are detailed in Table 2. A combination of FDR%pred. with absolute 
blood eosinophil counts demonstrated the best predictive capacity (AUC = 0.85, p‑value = 0.01, CI95 = 0.67–1.00)
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of 87%, and AUC of 85% [67–100%], (CI = 0.95, p = 0.01) 
(Fig. 1).
Within response groups, responders to anti-T2 bio-
logical therapies experienced significant improvements 
in all clinical markers (i.e. lung function, inflammatory 
biomarkers) in contrast to partial/non-responders that 
did not demonstrate any statistically significant changes; 
details are given in (Table 1).
Linear regressions indicated better associations 
between improvements in FDR and ACT score than 
with FEV1 and ACT score as well as better associations 
between improvements in FDR and reduction of exacer-
bations than with FEV1 (Fig. 2). The other included lung 
function measures  (FEF25–75, RV and RV/TLC) were not 
superior to FEV1 when correlated to improvements in 
exacerbations or ACT with  R2 values around 0.20.
The main finding of our study is that SAD improves 
substantially under anti-T2 biological therapy in patients 
with severe eosinophilic asthma. Furthermore, pre-treat-
ment IOS measures of SAD demonstrated to be mean-
ingful predictors of clinical response, thereby indicating 
that severe SAD might describe a distinct phenotype 
with therapeutic implications among patients with severe 
eosinophilic asthma. Our results are consistent with the 
findings of previous studies which indicated that meas-
ures of SAD like  FEF25-75, lung clearance index, regional 
ventilation inhomogeneity in acinar and conducting 
airways improve significantly under biological therapy 
[20, 21]. Oscillometric measures of SAD seem to be fea-
sible tools in selecting appropriate patients qualifying 
for anti-T2 biological therapy beyond the rather crude 
measurement of baseline blood eosinophils count that is 
frequently influenced by a multitude of factors, e.g. dose 
of inhaled or oral steroids [22], diurnal variations [23] 
Fig. 2 comparative linear regressions: between small airway dysfunction (FDR, KPa/L/s) and airflow limitation (FEV1, ml) in correlation to ACT 
score (points) and reduction in exacerbations (%). All values represent the difference (delta) between baseline and under therapy. A: linear 
regression between (delta ACT) scores on the x‑axis, and the change in FDR (delta R5‑20), y‑axis:  R2 = 0.42, DF = 18, p = 0.001. B: linear regression 
between (delta ACT) scores on the x‑axis and the change in FEV1 (delta FEV1), y‑axis:  R2 = 0.25, DF = 18, p = 0.013. C: linear regression between 
(delta exacerbations) on the x‑axis and the change in FDR (delta FEV1), y‑axis:  R2 = 0.41, DF = 18, p = 0.001. D: linear regression between (delta 
exacerbations) on the x‑axis and the change in FEV1 (delta R5‑20), y‑axis:  R2 = 0.20, DF = 18, p = 0.025
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and atopic comorbidities [24]. Our observations on the 
improvements in SAD might be explained by the find-
ings that in severe asthmatics, small airway function is 
significantly altered with type-2 inflammation (T cells 
and activated eosinophils infiltration) compared to large 
airways [25, 26]. In our study, partial or non-responders 
experienced a 58% mean reduction of circulating blood 
eosinophils (p > 0.05), indicating the pharmacological 
effect of the biological therapy without marked improve-
ments in clinical symptoms. These results are consistent 
with the finding of Kelly et al., which showed that despite 
the clear reduction in circulating and airway eosinophilia 
under mepolizumab, it does not suppress other eosino-
phil activation markers which might explain the clinical 
deterioration in some subjects [27].
The main limitations of this study are its observational 
nature and the small number of the included subjects. 
Further, additional measures of small airway function 
like inert gas distribution could have supported our find-
ings. Therefore, clinical trials involving larger cohorts and 
multimodular assessment of small airway function are 
needed to confirm our observation. Finally, two patients 
had a treatment with either dupilumab or benralizumab 
which do not share the exact same pharmacological 
mechanism compared with mepolizumab.
Our data support that SAD is potentially linked to 
asthma control as SAD improves substantially under 
anti-T2 biological therapy in therapy responders. Meas-
ures of small airway function like the FDR might be use-
ful in selecting appropriate patients qualifying for anti-T2 
biological therapy in addition to blood eosinophil count 
and might also serve as markers to assess clinical treat-
ment response in patients with newly initiated biological 
therapy.
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